Radioactive antibody plus immunotherapy shows promise in kidney cancer trial
NCT ID NCT05239533
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a combination of two drugs—nivolumab (an immunotherapy) and a radioactive antibody called 177Lu-girentuximab—in people with advanced clear cell kidney cancer that has the CAIX protein. The goal is to find the safest dose and see if the combination shrinks tumors. Only 9 participants are enrolled, so results are very early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab combined with a radioactive antibody (177Lu-girentuximab)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced clear cell kidney cancer that has not responded to other therapies.
- What could go wrong
- This is a very early, small phase 2 trial with only 9 participants. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activites)
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Could an ALS drug clear the fog of chemo brain?